FY2030 Earnings Estimate for ARWR Issued By B. Riley

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – B. Riley issued their FY2030 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a research note issued on Tuesday, November 25th. B. Riley analyst M. El-Saadi anticipates that the biotechnology company will earn $6.48 per share for the year. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share.

A number of other equities research analysts have also recently commented on ARWR. Piper Sandler raised their price objective on shares of Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Morgan Stanley boosted their price objective on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an “equal weight” rating in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. The Goldman Sachs Group increased their price target on Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the company a “neutral” rating in a report on Thursday, November 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.56.

Arrowhead Pharmaceuticals Price Performance

NASDAQ ARWR opened at $57.71 on Thursday. Arrowhead Pharmaceuticals has a 1 year low of $9.57 and a 1 year high of $59.15. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. The company has a market cap of $7.98 billion, a price-to-earnings ratio of -45.09 and a beta of 1.27. The stock’s fifty day moving average price is $38.18 and its 200 day moving average price is $25.40.

Insider Buying and Selling

In related news, insider James C. Hamilton sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the transaction, the insider directly owned 212,122 shares in the company, valued at $7,424,270. The trade was a 8.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders have sold 50,000 shares of company stock valued at $1,525,000. 4.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of large investors have recently modified their holdings of ARWR. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Arrowhead Pharmaceuticals by 138.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock valued at $60,962,000 after purchasing an additional 2,774,933 shares in the last quarter. Marshall Wace LLP grew its holdings in Arrowhead Pharmaceuticals by 3,507.8% in the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock worth $34,065,000 after buying an additional 2,096,238 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Arrowhead Pharmaceuticals by 3,142.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock worth $71,797,000 after buying an additional 2,017,489 shares in the last quarter. Norges Bank acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at $30,414,000. Finally, Vanguard Group Inc. grew its position in Arrowhead Pharmaceuticals by 8.4% in the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock worth $168,201,000 after buying an additional 1,018,273 shares during the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.